Wedbush Initiates Coverage on Abbott Laboratories (ABT) with an Outperform; Fast-Expanding Product Mix
ABT Hot Sheet
Rating Summary:3 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Wedbush initiates coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating. Price target $62.
Wedbush analyst says, "During the next several years, we expect investors to reap the benefits of ABT’s recent financial and strategic moves: We expect these benefits to take the form of strong top-line growth, improved margins, sustained double-digit earnings growth, and strong cash returns to shareholders in the form of double-digit annual dividend increases. Most of the impact of efforts to improve operating leverage will reach their peak in the 2011-2012 timeframe."
"ABT has a long history of successfully integrating acquisitions and improving its business mix. Recent deals such as the purchase of Advanced Medical Optics and the pending acquisition of Solvay Pharmaceuticals further diversified ABT’s portfolio of businesses and broaden its geographic reach, thus improving the overall risk profile. Beyond M&A, we expect ABT to become more active in partnerships and alliances as a means to increase the R&D pipeline."
To see more analyst ratings on ABT Click Here.
Abbott Laboratories manufactures and sells health care products worldwide.
Wedbush analyst says, "During the next several years, we expect investors to reap the benefits of ABT’s recent financial and strategic moves: We expect these benefits to take the form of strong top-line growth, improved margins, sustained double-digit earnings growth, and strong cash returns to shareholders in the form of double-digit annual dividend increases. Most of the impact of efforts to improve operating leverage will reach their peak in the 2011-2012 timeframe."
"ABT has a long history of successfully integrating acquisitions and improving its business mix. Recent deals such as the purchase of Advanced Medical Optics and the pending acquisition of Solvay Pharmaceuticals further diversified ABT’s portfolio of businesses and broaden its geographic reach, thus improving the overall risk profile. Beyond M&A, we expect ABT to become more active in partnerships and alliances as a means to increase the R&D pipeline."
To see more analyst ratings on ABT Click Here.
Abbott Laboratories manufactures and sells health care products worldwide.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
New CoverageRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
